Rivogenlecleucel

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameRivogenlecleucel
Drug Alias NameBPX-501-AP-1903BPX-501-rimiducidBPX501-AP1903rivo-celBPX-501 and AP1903 +[7] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunostimulantsT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmCytopeniaMetabolic Diseases +[27] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBellicum Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesBellicum Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsCytopeniaPrimary Immunodeficiency DiseasesHemoglobinopathies +[11] 
Inactive IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmMetabolic DiseasesLymphohistiocytosis, Hemophagocytic +[16] 

Other Information

ATC CodeN/A
Related LinksN/A